The Possible Role of Flavonoids in the Prevention of Diabetic Complications

Related Experiment Video

Updated: Mar 20, 2026

Preparation of Naringenin Solution for In Vivo Application
08:18

Preparation of Naringenin Solution for In Vivo Application

Published on: August 10, 2021

3.9K

Roberto Testa1, Anna Rita Bonfigli2, Stefano Genovese3

  • 1Experimental Models in Clinical Pathology, INRCA-IRCCS National Institute, Ancona I-60127, Italy. r.testa@inrca.it.

Nutrients
|May 24, 2016
PubMed

Insights

Flavonoids show promise in managing type 2 diabetes mellitus (T2DM) by impacting metabolic pathways and potentially mitigating diabetic complications. Further research highlights their role in T2DM management.

Area of Science:

  • Biochemistry
  • Metabolic Diseases
  • Nutritional Science

Background:

  • Type 2 diabetes mellitus (T2DM) involves complex metabolic dysfunctions including insulin resistance, beta-cell issues, and oxidative stress.
  • T2DM complications encompass neuropathy, retinopathy, nephropathy, and cardiovascular disease.
  • Emerging evidence suggests flavonoids influence metabolic processes relevant to T2DM.

Purpose of the Study:

  • To review recent literature on the role of flavonoids in T2DM.
  • To highlight the relationship between flavonoids and major diabetic complications.

Main Methods:

  • Literature review of in vitro, animal, and human studies.
  • Focus on recent publications concerning flavonoids and diabetic complications.

Main Results:

  • Flavonoids demonstrate potential roles in metabolic pathways affected by T2DM.
  • Evidence links flavonoids to the modulation of factors contributing to diabetic complications.

Conclusions:

  • Flavonoids may offer therapeutic benefits for T2DM and its associated complications.
  • Further investigation into flavonoid mechanisms in T2DM is warranted.
Keywords:
diabetic complicationsflavonoidstype 2 diabetes mellitus

More Related Videos

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade09:50

Biosynthesis of a Flavonol from a Flavanone by Establishing a One-pot Bienzymatic Cascade

Published on: August 14, 2019

9.9K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

26.7K

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
8.6K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
4.2K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
908
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.4K
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.7K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
837